ReligenDx is developing new and innovative diagnostic tests, focusing on neurodevelopmental and mitochondrial diseases. The critical step to creating new diagnostic tests is to identify effective biomarkers that can be used to facilitate appropriate intervention and treatment at the earliest stages. ReligenDx has already pioneered a number of diagnostic tests with a therapeutic focus on mitochondrial disease, cardiovascular disease and neurodegenerative diseases. This includes MitoSwab, a buccal swab test that analyzes the function of the Mitochondrial Electron Transport Chain complex. The non-invasive test is quantitative and can assist in developing therapeutic strategies for mitochondrial health.

ReligenDx

Founded: 2018
Location: Plymouth Meeting, PA
Employee range: 11 - 50
Funding: not disclosed

Short description:

Drug notes:

Long description:

Jobs: